BioSpace News Archive

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announces that The Lancet published online positive results from a Phase 3 pivotal clinical trial of rimegepant Zydis® orally dissolving tablet (ODT) for the acute treatment of migraine.

The Galien Foundation today announced the 2019 Annual Prix Galien USA Award nominees. Counted among the global health innovation industry’s most prized honors, the Prix Galien Award recognizes outstanding biomedical and medical technology product achievement that improves the human condition.

ESSA Pharma Inc. (“ESSA” or “the Company”) (NASDAQ: EPIX; TSX-V: EPI), a pharmaceutical company focused on the developing novel therapies for the treatment of prostate cancer, announced today the appointment of Dr. Alessandra Cesano, M.D., PhD as Chief Medical Officer (“CMO”).

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2019 after the U.S. markets close on August 6, 2019.

AbbVie (NYSE: ABBV) announced today that it has acquired Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors provided an operational update and released financial results for the fiscal year ended April 30, 2019.

Inscopix today announced a new research collaboration with Biogen to research and develop a new class of therapies for chronic pain.

Hoth Therapeutics, Inc. (Nasdaq: HOTH) today announced that it has entered into an exclusive license option agreement with the George Washington University (GW) pertaining to its intellectual property on the use of Aprepitant in treating skin-related and other side effects from drugs used to treat cancer

Acquisition adds key platform supporting Boehringer Ingelheim’s focus on patients with difficult-to-treat gastrointestinal and lung cancers

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ company, developing targeted therapies to treat cancers with significant medical need for new treatment options, is pleased to release to shareholders and investors its latest Company Presentation ahead of commencing a roadshow to investment institutions, analysts and shareholders in New York City.